Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • Matina
    Junior Member
    • Jun 2012
    • 6

    Comparison between different batches and global analysis

    Hello everyone,

    I have RNA-seq data coming from control, breast cancer and endometrial cancer patients. Is an ongoing study and so far we've sequenced 15 patients (5 control, 5 breast cancer and 5 endometrial cancer) about a year ago and 5 patients (1 control, 2 breast cancer and 2 endometrial cancer) a month ago.

    I want to compare between the independent batches and also combine them and do a global analysis. I did an independent DE analysis on each batch using EdgeR and DESeq2 however when i compare the gene lists I have very few common DE genes. Do I need to do some kind of normalisation before i compare them? About the global analysis, I will put everything together but how can I correct for batch effects?

    Thank you so much!
  • blancha
    Senior Member
    • May 2013
    • 367

    #2
    Just a general comment first.
    I've have very poor results regarding correlation between human clinical samples.
    There are too many variables that are not controlled for.
    Often, when you enquire about the collection method of the samples, you'll find that they are not identical for all samples, e.g. some samples were frozen for a long period of time, the tumor samples contain different proportions of normal tissue, ...
    I've often been unpleasantly surprised that the samples that were described to me as replicates actually had significant differences.
    The best results are generally obtained when the person collecting the samples is experienced in RNA-Seq analysis, and is aware how the collection and preparation of the samples can affect the downstream analysis.

    There are also variations between cancers, but that is biologically relevant.

    As an analyst, you need to get as much information as possible about the collection method of the samples, and collect as much metrics as possible to better understand the samples (e.g. RNA integrity number for all the samples, exotic alignment rate, ...).

    -----

    Second, you have few or no replicates in your second batch so you would expect DESeq and edgeR to give you a different list of differentially expressed genes. In the second batch for example, you have no control replicates which will affect the calculation of the dispersion level by DESeq and edgeR.

    -----

    To answer your question though, I would first try clustering the samples using the normalized counts. If the samples do no cluster according to the tissue of origin but rather according to the batch, I would try removing the batch effect with ComBat. I would then repeat the clustering to verify if ComBat has successfully removed the batch effect.
    Last edited by blancha; 05-18-2014, 10:01 AM.

    Comment

    • Matina
      Junior Member
      • Jun 2012
      • 6

      #3
      Thank you very much for you answer blancha.
      I'll try using comBat!

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      19 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-23-2026, 11:41 AM
      0 responses
      19 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-20-2026, 11:10 AM
      0 responses
      25 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-13-2026, 10:26 AM
      0 responses
      38 views
      0 reactions
      Last Post SEQadmin2  
      Working...